Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma

Trial Profile

Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Fluorouracil (Primary) ; Mitomycin (Primary) ; Panitumumab (Primary)
  • Indications Anal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VITAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top